Aimmune Therap (AIMT) Stock Price, Quote, News and Overview
NASDAQ:AIMT - Nasdaq -
AIMT Quote, Performance and Key Statistics
34.49
-0.1 (-0.29%)
The current stock price of AIMT is 34.49 null. In the past month the price increased by 0.52%. In the past year, price increased by 37.14%.
About AIMT
Company Profile
Aimmune Therapeutics, Inc. is a biopharmaceutical company which is engaged in the development of desensitization treatments for peanut and other food allergies. The Company's characterized oral desensitization immunotherapy includes AR101, a product for the treatment of peanut allergy in children and adults which is in clinical trial stage. Aimmune Therapeutics, Inc. is headquartered in Brisbane, California.
Company Info
Aimmune Therap
8000 MARINA BOULEVARD SUITE 300
BRISBANE CA 94005
CEO: Jayson Dallas
Phone: 650-614-5220
Aimmune Therap / AIMT FAQ
What is the stock price of Aimmune Therap today?
The current stock price of AIMT is 34.49 null. The price decreased by -0.29% in the last trading session.
What is the ticker symbol for Aimmune Therap stock?
The exchange symbol of Aimmune Therap is AIMT and it is listed on the Nasdaq exchange.
On which exchange is AIMT stock listed?
AIMT stock is listed on the Nasdaq exchange.
What is Aimmune Therap worth?
Aimmune Therap (AIMT) has a market capitalization of 2.26B null. This makes AIMT a Mid Cap stock.
What are the support and resistance levels for Aimmune Therap (AIMT) stock?
Aimmune Therap (AIMT) has a support level at 34.48 and a resistance level at 35.1. Check the full technical report for a detailed analysis of AIMT support and resistance levels.
Should I buy Aimmune Therap (AIMT) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of AIMT, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of AIMT, evaluating the profitability, health, valuation and growth aspects
- Aimmune Therap (AIMT) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- Aimmune Therap (AIMT) Sales and EPS estimates to see what analysts future expectations are.
- Aimmune Therap (AIMT) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- Aimmune Therap (AIMT) Insider and Institutional Ownership to learn about the owners and their transactions.
- Aimmune Therap (AIMT) Stock Chart to make your own analysis
- Aimmune Therap (AIMT) Latest news and press-releases to stay up to date.
Does Aimmune Therap (AIMT) stock pay dividends?
AIMT does not pay a dividend.
What is the Price/Earnings (PE) ratio of Aimmune Therap (AIMT)?
Aimmune Therap (AIMT) does not have a PE ratio as the earnings reported over the last twelve months were negative (-4.33).
AIMT Technical Analysis
ChartMill assigns a technical rating of 8 / 10 to AIMT. When comparing the yearly performance of all stocks, AIMT is one of the better performing stocks in the market, outperforming 95.58% of all stocks.
AIMT Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to AIMT. While AIMT seems to be doing ok healthwise, there are quite some concerns on its profitability.
AIMT Financial Highlights
Over the last trailing twelve months AIMT reported a non-GAAP Earnings per Share(EPS) of -4.33. The EPS decreased by -16.4% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | -49918.09% | ||
| ROA | -78.58% | ||
| ROE | N/A | ||
| Debt/Equity | 0.73 |
AIMT Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 73% to AIMT. The Buy consensus is the average rating of analysts ratings from 9 analysts.